Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells

Annals of Surgical Innovation and Research

Volumn 3, Issue , 2009, Pages

  Reimers, Kerstin ^a   Radtke, Christine ^a   Choi, Claudia Y ^a   Allmeling, Christina ^a   Kall, Susanne ^a   Kiefer, Paul ^b   Muehlberger, Thomas ^a   Vogt, Peter M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955226080     PISSN: None     EISSN: 17501164     Source Type: Journal    
DOI: 10.1186/1750-1164-3-13     Document Type: Article

References (35)

1. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002, 27(1):19-26. 10.1016/S0968-0004(01)01995-8, 11796220.
2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3(6):673-682. 10.1016/1074-7613(95)90057-8, 8777713.
3. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276(5309):111-113. 10.1126/science.276.5309.111, 9082980.
4. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271(22):12687-12690. 10.1074/jbc.271.22.12687, 8663110.
5. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277(5327):818-821. 10.1126/science.277.5327.818, 9242611.
6. Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol 1998, 28(1):143-152. 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3, 9485194.
7. Phillips TA, Ni J, Pan G, Ruben SM, Wei YF, Pace JL, Hunt JS. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J Immunol 1999, 162(10):6053-6059.
8. Sundstrom JB, Ansari AA. Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts. Transpl Immunol 1995, 3(4):273-289. 10.1016/0966-3274(95)80013-1, 8665146.
9. Jones ND, Turvey SE, Van Maurik A, Hara M, Kingsley CI, Smith CH, Mellor AL, Morris PJ, Wood KJ. Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J Immunol 2001, 166(4):2824-2830.
10. Youssef AR, Otley C, Mathieson PW, Smith RM. Role of CD4+ and CD8+ T cells in murine skin and heart allograft rejection across different antigenic desparities. Transpl Immunol 2004, 13(4):297-304. 10.1016/j.trim.2004.10.005, 15589743.
11. Woodley DT, Peterson HD, Herzog SR, Stricklin GP, Burgeson RE, Briggaman RA, Cronce DJ, O'Keefe EJ. Burn wounds resurfaced by cultured epidermal autografts show abnormal reconstitution of anchoring fibrils. JAMA 1988, 259(17):2566-2571. 10.1001/jama.259.17.2566, 3282083.
12. Monleon I, Martinez-Lorenzo MJ, Monteagudo L, Lasierra P, Taules M, Iturralde M, Pineiro A, Larrad L, Alava MA, Naval J, Anel A. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol 2001, 167(12):6736-6744.
13. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998, 28(3):973-982. 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T, 9541592.
14. Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K, Yagita H. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999, 162(5):2639-2647.
15. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998, 10(5):559-563. 10.1016/S0952-7915(98)80224-0, 9794836.
16. Cappellesso S, Thibault G, Hoarau C, Hérault O, Iochmann S, Bardos P, Lebranchu Y. FasL-transfected endothelial cells decrease the proliferative response of allogeneic PBL. Transpl Immunol 2002, 10(4):293-302. 10.1016/S0966-3274(02)00073-4, 12507401.
17. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002, 80(2):131-137. 10.1046/j.1440-1711.2002.01068.x, 11940113.
18. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. Fas counter-attack-the best form of tumor defense?. Nat Med 1999, 5(3):267-268. 10.1038/6477, 10086376.
19. Restifo NP. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000, 6(5):493-495. 10.1038/74955, 1955754, 10802692.
20. Mann B, Gratchev A, Bohm C, Hanski ML, Foss HD, Demel G, Trojanek B, Schmidt-Wolf I, Stein H, Riecken EO, Buhr HJ, Hanski C. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999, 79(7-8):1262-1269. 10.1038/sj.bjc.6690202, 2362258, 10098769.
21. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000, 6(9):3560-3564.
22. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997, 94(12):6420-6425. 10.1073/pnas.94.12.6420, 21065, 9177233.
23. Yoong KF, Afford SC, Randhawa S, Hubscher SG, Adams DH. Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol 1999, 154(3):693-703. 1866426, 10079247.
24. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998, 160(11):5669-5675.
25. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996, 184(3):1075-1082. 10.1084/jem.184.3.1075, 2192789, 9064324.
26. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270(5239):1189-1192. 10.1126/science.270.5239.1189, 7502042.
27. Inoue H, Shiraki K, Yamanaka T, Ohmori S, Sakai T, Deguchi M, Okano H, Murata K, Sugimoto K, Nakano T. Functional expression of tumor necrosis factor-related apoptosis-inducing ligand in human colonic adenocarcinoma cells. Lab Invest 2002, 82(9):1111-1119.
28. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000, 6(5):564-567. 10.1038/75045, 10802713.
29. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, Deforge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001, 7(4):383-385. 10.1038/86397, 11283636.
30. Mariani SM, Krammer PH. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol 1998, 28(5):1492-1498. 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X, 9603453.
31. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5(2):157-163. 10.1038/5517, 9930862.
32. Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, Bitzer M. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003, 63(10):2369-2372.
33. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T, Suzuki A. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000, 32(3):482-490. 10.1053/jhep.2000.16266, 10960439.
34. Bodmer JL, Meier P, Tschopp J, Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 2000, 275(27):20632-20637. 10.1074/jbc.M909721199, 10748154.
35. Trabzuni D, Famulski KS, Ahmad M. Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem J 2000, 350(Pt 2):505-510. 10.1042/0264-6021:3500505, 1221278, 10947965.